Venture Life Group (LON:VLG) Insider Paul McGreevy Purchases 48,373 Shares

Venture Life Group plc (LON:VLG) insider Paul McGreevy purchased 48,373 shares of Venture Life Group stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average price of GBX 62 per share, with a total value of £29,991.26.

Paul McGreevy also recently made the following trade(s):

• On Wednesday, June 3rd, Paul McGreevy acquired 15,663 shares of Venture Life Group stock. The shares were acquired at an average price of GBX 64 per share, for a total transaction of £10,024.32.
• On Wednesday, June 3rd, Paul McGreevy acquired 8,066 shares of Venture Life Group stock. The shares were acquired at an average cost of GBX 62 per share, for a total transaction of £5,000.92.
• On Wednesday, June 3rd, Paul McGreevy acquired 8,105 shares of Venture Life Group stock. The shares were acquired at an average cost of GBX 62 per share, for a total transaction of £5,025.10.

Venture Life Group Stock Performance

Shares of LON:VLG opened at GBX 66.75 on Thursday. The firm has a 50 day moving average of GBX 61.09 and a 200 day moving average of GBX 64.11. The company has a quick ratio of 1.48, a current ratio of 4.71 and a debt-to-equity ratio of 0.82. The company has a market capitalization of £81.32 million, a price-to-earnings ratio of 15.27, a price-to-earnings-growth ratio of 5.67 and a beta of 0.24. Venture Life Group plc has a 52 week low of GBX 49 and a 52 week high of GBX 72.

Venture Life Group (LON:VLG) last announced its earnings results on Tuesday, March 31st. The company reported GBX (1.49) earnings per share (EPS) for the quarter. Venture Life Group had a net margin of 17.42% and a return on equity of 7.82%. The company had revenue of GBX 3,517 million for the quarter. On average, sell-side analysts predict that Venture Life Group plc will post 6.1391542 earnings per share for the current fiscal year.

About Venture Life Group

Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.

Headquartered in the UK, the Group’s product portfolio includes Balance Activ in the area of women’s intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.